Nanotechnology Characterization Laboratory (NCL)
|
Research Initiative
|
FDA
|
|
2004
|
|
NAPA Federal Subgroup
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS
|
NINDS
|
2014
|
|
NASEM Forum on Drug Discovery, Development, and Translation
|
Committee, Advisory Group, or Work Group
|
FDA, ASPR
|
NINDS, NIAID, NCI, NIMH, OD/ OSP, NCATS
|
|
|
NASEM Forum on Neuroscience and Nervous System Disorders
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCCIH, NIMH, NIAAA, NIA, NIEHS, NIDA
|
2006
|
|
National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2020
|
|
National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) 2020-2025
|
Committee, Advisory Group, or Work Group
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
2019
|
|
National Advisory Committee on Children and Disasters (NAACD)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, ASPR
|
NICHD, NIEHS
|
|
|
National Biodefense Strategy - Vaccines Joint Capabilities Plan writing group
|
Other
|
ASPR, CDC, FDA
|
NIAID
|
2022
|
|
National Center for Advancing Translational Sciences (NCATS) Toolkit for Patient-focused Therapy Development
|
Resource Development
|
FDA
|
NCATS
|
2017
|
|
National Clinical Trials Network (NCTN) Scientific Steering Committees (SSCs)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2008
|
|
National Coalition for Oversight of Assisted Reproductive Technologies (NCOART)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
1997
|
|
National COVID Cohort Collaborative (N3C)
|
Research Initiative
|
FDA, ASPR, CMS
|
NCATS, NIGMS
|
2021
|
|
National Database for Antibiotic Resistant Organisms (NDARO)
|
Resource Development
|
CDC, FDA
|
CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIDA
|
2016
|
|
National Emerging Contaminant Research Initiative
|
Research Initiative
|
CDC, ATSDR, FDA
|
|
|
|
National Food and Nutrient Analysis Program (NFNAP)
|
Committee, Advisory Group, or Work Group
|
CDC, IHS, FDA
|
NHLBI, NEI, NIA, NICHD, NIDCR, NIDDK, CSR, NIEHS, OD
|
1997
|
|
National HIV/AIDS Strategy Steering Committee (NHAS)
|
Committee, Advisory Group, or Work Group
|
OASH, CDC, HRSA, IHS, SAMHSA, CMS, FDA, ACL, AHRQ
|
NIAID, NIDDK, OD/ DPCPSI/ OAR
|
2021
|
|
National Hospital Care Survey (NHCS) Patient-Centered Outcomes Research Trust Fund (PCORTF) Project
|
Other
|
CDC, SAMHSA, ASPE, FDA
|
NIDA, NIMH
|
|
|
National Institutes of Health (NIH) Flow Cytometry Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NEI, NHLBI, NIAID, NIAMS, NIDCR
|
2005
|
|
National Interagency Confederation for Biological Research
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2002
|
|
National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
NIBIB
|
2012
|
|
National PAD Action Plan
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA
|
NIA, NIDDK
|
2018
|
|
National Science Advisory Board for Biosecurity
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2004
|
|
National Sexually Transmitted Infections (STI) Strategic Plan
|
Committee, Advisory Group, or Work Group
|
OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIAID
|
2020
|
|
National Toxicology Board of Scientific Counselors (NTP BSC)
|
Meeting/ Workshop
|
CDC, FDA
|
|
1978
|
|
National Toxicology Program Executive Committee (NTP EC)
|
Meeting/ Workshop
|
ATSDR, CDC, FDA, OASH
|
|
1978
|
|
National Toxicology Program Steering Committee (NTP SC)
|
Meeting/ Workshop
|
CDC, FDA
|
|
2003
|
|
NBS Implementation Plans Joint Capabilities Plans-Clinical Research Capacity, Therapeutics
|
Committee, Advisory Group, or Work Group
|
FDA, ASPR
|
NIAID
|
2022
|
|
NCATS N3C Collaboration
|
Resource Development
|
FDA
|
NCATS
|
2020
|
|
NCI Cancer Data Standards Repository and Registry (caDSR)
|
Committee, Advisory Group, or Work Group
|
FDA, ASPE
|
CIT, NEI, NHLBI, NIAMS, NIBIB, NICHD, NIMH, NINDS, NLM, NIDA, NIDCD, NCATS
|
2000
|
|
NCI Cervical Cancer "Last Mile" Initiative (LMI)
|
Research Initiative
|
FDA, CDC
|
|
2021
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
|
2007
|
|
NCI Enterprise Vocabulary Services (EVS) controlled terminology and standards development in collaboration with FDA and international regulatory agencies including NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
|
2012
|
|
NCI Fecal Microbiota Transplants and Defined Microbiota Cancer Therapeutics Clinical Research Working Group/NCI Convenes Workshop on Reproducibility of Fecal Microbiota Transplants in Cancer Therapeutics
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2019
|
|
NCI Multi-Cancer Detection (MCD) Trial Team
|
Research Initiative
|
CMS, FDA
|
OD/ DPCPSI/ ORWH
|
2021
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
|
2015
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
|
2007
|
|
NEI-FDA-ONC Joint Workshop on Promoting Adoption of Ocular Imaging Standards
|
Meeting/ Workshop
|
ONC, FDA
|
|
2021
|
|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, FDA, HRSA, IOS, AHRQ
|
NHGRI, NHLBI, NICHD
|
2007
|
|
Newborn Screening Federal Partners Committee
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NLM
|
2009
|
|
Next Generation Microfluidics Workshop
|
Meeting/ Workshop
|
FDA
|
|
2021
|
|
NF-kappaB in pathogenesis and therapy of head and neck cancer
|
Research Initiative
|
FDA
|
NICHD
|
|
|
NIA Confocal Imaging Facility
|
Research Initiative
|
FDA
|
NIA
|
|
|
NIAID/FDA/BARDA Meeting on Gastrointestinal Acute Radiation Syndrome (GI-ARS)
|
Meeting/ Workshop
|
FDA, ASPR
|
|
2021
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Advisory Group, or Work Group
|
BARDA, FDA
|
NCI, NHLBI
|
2017
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDA
|
2013
|
|
NIDA-FDA Interagency Clinical Outcomes Assessment Working Group (ICOAWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDA, NCI, OD/ DPCPSI/ OBSSR
|
|
|
NIEHS SBIR PHASE IIB Awards for Validation and Commercialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2016
|
|
NIH Autoimmune Diseases Coordinating Committee (ADCC)
|
Committee, Advisory Group, or Work Group
|
FDA, HRSA
|
NIAID, OD, NCI, NCATS, NCCIH, NEI, NHLBI, NHGRI, NIAMS, NIBIB
|
2003
|
|
NIH Common Data Elements Task Force (CDETF)
|
Committee, Advisory Group, or Work Group
|
AHRQ, FDA, CMS, ASPE, CDC
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NINDS, NINR, NLM, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODSS, OD/ OER, OD/ AoU, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ SGMRO, OD/ ECHO, NIGMS, NIMH, NIMHD
|
2012
|
|
NIH COVID-19 Treatment Guidelines Panel
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2020
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI, OD/ OER
|
2007
|
|
NIH-FDA Interagency Clinical Outcome Assessments Working Group (ICOAWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ SGMRO
|
2010
|
|
NIH-FDA Medical Device Research Interest Group (MDRIG)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCATS, NCI, NEI, NHLBI, NIA, NIAID, NIBIB, NICHD, NIDDK, NINR, OD/ DPCPSI/ ORIP, FIC, NIAMS, NIDA, NCCIH, NHGRI, NIAAA, NIDCD, NIGMS, NIEHS, NLM, OD
|
2016
|
|
NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, FDA, CDC
|
NIAID
|
2015
|
|
NINDS Common Data Elements Program
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
CIT, NINDS, NICHD, NEI, NHGRI, NCATS, NIA, NIMH, NIEHS, NIGMS, NIBIB, NIDDK, NIDCR, NINR, NHLBI
|
2006
|
|
NITRD Digital Health R&D Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, FDA, ONC
|
NCATS, NHLBI, NIA, NIMH, NIBIB, NICHD, OD/ DPCPSI/ OBSSR, OD/ OSP
|
2011
|
|
Non-animal approaches to assess cardiotoxicity hazard
|
Research Initiative
|
FDA
|
|
2018
|
|
Noroviruses and Epidemic Gastroenteritis
|
Research Initiative
|
FDA
|
NIAID
|
|
|
NSTC Subcommittee on Biological Sciences
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
OD/ OSP
|
|
|
NSTC Subcommittee on Open Science (NSTC SOS)
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPR, CDC, FDA
|
OD/ DPCPSI/ ODSS
|
2016
|
|
Nutrition Research Coordinating Committee (NRCC)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, CDC, FDA, HRSA, OASH
|
NCATS, NCCIH, FIC, CSR, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI, OD/ DPCPSI/ OAR, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODS, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ OSC, OD/ ECHO
|
1975
|
|
|